Physician profile
Christopher Bianco
NPI 1285877688
$117,415.91
in general payments reported to CMS, 2019-2025
15 companies · $15K in 2025
The $15K reported for 2025 was more than what 81% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $310 · 2020: $3,257 · 2021: $12K · 2022: $37K · 2023: $24K · 2024: $26K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $59K · Travel and Lodging: $3,106 · Food and Beverage: $2,377 · Consulting Fee: $1,160 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $58,699.00 |
| Travel and Lodging | $3,106.12 |
| Food and Beverage | $2,376.57 |
| Consulting Fee | $1,160.00 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $69,470.05 | 2021-2025 | Camzyos, Eliquis |
| Pfizer INC. | $39,898.65 | 2020-2024 | |
| Alnylam Pharmaceuticals INC. | $6,148.43 | 2021-2024 | Onpattro, Amvuttra |
| Celgene Corporation | $494.31 | 2022-2024 | Camzyos |
| Abbott Laboratories | $457.35 | 2019-2024 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $215.63 | 2019-2024 | Lifevest |
| Vifor Pharma, INC. | $200.00 | 2021 | |
| Cvrx, INC. | $169.10 | 2021-2025 | Barostim Neo System |
| Novo Nordisk INC | $101.55 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $91.70 | 2019-2024 | |
| Abiomed | $67.38 | 2024 | Impella |
| Impulse Dynamics (USA) INC. | $50.14 | 2023 | Optimizer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.38 | 2023-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $17.24 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Bianco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.